Media.Player

Organ Resuscitation Solution & System for Enhanced Liver Transplantation

技術優勢

The invention represents the first type of organ resuscitation technology for transplantation procedures.

技術應用

Liver resuscitation before transplantation. Other transplantable organ resuscitation (e.g. kidney, pancreas, pancreas, lung, etc.)

詳細技術說明

Dr. Johnny C. Hong, a Professor in the Department of Surgery and UCLA Pfleger Liver Institute, has developed a novel solution and system to minimize IRI associated with liver transplantation. The invention serves to replenish exhausted nutrients and resuscitate the organ before revascularization. In a swine model, use of the novel solution and system demonstrated enhanced liver function and improved survival compared to conventional approaches. This system may salvage livers, deemed to have incurred severe degree of ischemic injury and discarded, to transplantable organs. The system could potentially be applied to other transplantable organs. A solution and system to alleviate organ damage from IRI would have significant consequences on patient outcomes as well as the availability of transplantable organs. Over 2000 patients die annually in the United States while awaiting a liver transplant. Thus, increasing the number of available livers for organ transplantation could have huge benefit for the 16,000 patients awaiting a new liver.

*Abstract

None

*Applications

• Liver resuscitation before transplantation.
• Other transplantable organ resuscitation (e.g. kidney, pancreas, pancreas, lung, etc.)

*IP Issue Date

Nov 6, 2014

*Principal Investigation

Name: Johnny Hong

Department:

附加資料

Inventor: HONG, Johnny C.
Priority Number: WO2013082458A1
IPC Current: A61K000908 | A61K003170 | A61K00317076 | A61K004730
Assignee Applicant: The Regents of the University of California
Title: REPERFUSION PROTECTION SOLUTION AND USES THEREOF | SOLUTION DE PROTECTION DE REPERFUSION ET SES UTILISATIONS
Usefulness: REPERFUSION PROTECTION SOLUTION AND USES THEREOF | SOLUTION DE PROTECTION DE REPERFUSION ET SES UTILISATIONS
Summary: The organ reperfusion protection solution is useful for mitigating ischemic reperfusion injury in a solid organ of a mammal who is a human or a non-human mammal, where the organ is: a liver (preferred), a kidney, a pancreas, a spleen, heart, lungs, skin, an intestine, a composite tissue such as limbs or extremities; and a transplant organ (all claimed). Test details are described but no results given.
Novelty: Organ reperfusion protection solution used to mitigate ischemic reperfusion injury comprises buffer e.g. tromethamine, substrate e.g. aspartate to form ATP, citrate-phosphate-dextrose and amino acid e.g. glycine to stabilize cell membranes

主要類別

生物醫學

細分類別

醫藥成分

申請號碼

20140329221

其他

State Of Development

Dr. Hong's group has conducted preliminary studies in animal models. Using the novel system and solution, they have observed improved post-operative survival, reduced levels of markers of liver damage, and improved liver cell viability.

Background

Liver organs suffer a tremendous degree of ischemia and reperfusion injury (IRI) during transplantation. The injury stems from the interruption of blood flow and depletion of nutrients to the organ in the period between donor organ procurement, preservation and transplantation into the recipient. Cell injury or death and metabolic changes accompany this cessation of blood flow and liver cells are further compromised upon revascularization of the organ in a process known as reperfusion injury. IRI is a significant problem and causes up to 12% of early organ failure and 15% to 25% of long-term graft dysfunction. Post-reperfusion syndrome has an incidence rate of up to 30% and can cause acute cardiovascular collapse leading to acute death of the patients. Moreover, IRI contributes to the ongoing crisis of transplantable organs because many potential organs from deceased donors are particularly susceptible to IRI. As such, these organs are discarded since these organs would lack sufficient function when transplanted. Currently, there is no procedure or treatment to mitigate these effects.

Tech ID/UC Case

22385/2012-292-0

Related Cases

2012-292-0

國家/地區

美國